Pentosan Polysulfate safety profile & UK regulatory status

This page summarises the published safety profile, contraindications, interactions, and UK regulatory status for Pentosan Polysulfate. It is a reference and not a clinical safety assessment. Pentosan Polysulfate is the active substance of the prescription medicine Elmiron; see the UK regulatory section below for what the MHRA has published.

Safety profile

Pentosan polysulfate has a regulatory safety database from its oral interstitial cystitis use, and the main long-term concern in it is retinal. Common adverse reactions. In the unblinded clinical trial of 2499 interstitial cystitis patients described in the FDA label, adverse events at 1 to 4% frequency included alopecia (4%), diarrhoea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%) and dizziness (1%). The label says alopecia began within the first 4 weeks of treatment and that 97% of alopecia cases were alopecia areata limited to a single area of the scalp. In a 380-patient, 32-week study of 300, 600 and 900 mg daily doses, most adverse events were mild and resolved without intervention (Nickel et al., Urology 2005). The FDA label reports that at 900 mg daily, a dose higher than the approved dose, rectal haemorrhage was reported in 15% of patients in the 380-patient study, and that in a separate 16-week phase 2 study in 100 men (51 PPS, 49 placebo) elevated liver function tests were reported as an adverse event in 11.8% (n=6) of PPS-treated patients versus 2% (n=1) on placebo. Injectable routes. The FDA label for oral Elmiron states: "A similar product that was given subcutaneously, sublingually, or intramuscularly (and not initially metabolized by the liver) is associated with delayed immunoallergic thrombocytopenia with symptoms of thrombosis and hemorrhage." The label does not name that product. Injectable use in knee osteoarthritis. In the 114-patient intramuscular pilot study, mild bruising at the injection site occurred in fewer than 1% of patients in both groups (Ghosh 2005). In the 20-patient open-label subcutaneous study, the dose used affected the blood coagulation tests but was reported to be within safe levels, and slightly abnormal serum triglycerides were noted (Kumagai 2010). The 61-participant phase 2 trial reported that subcutaneous PPS was well tolerated with no serious related adverse events or adverse events of special interest (Skerrett 2026). Pigmentary maculopathy. In a single-centre prospective screening study from UCLA, prevalence among PPS users who agreed to participate was 16% of 100 patients, with mean cumulative dosage of 3,103 g in the affected group versus 768 g in the unaffected group (Wang et al., Am J Ophthalmol 2021). An earlier cross-sectional study from the same centre found 20% (10/50), and its authors recommended annual retinal imaging, especially as cumulative dosage approaches 500 g, and judged that patients exposed to more than 1500 g are at significant risk (Wang et al., Can J Ophthalmol 2020). Both are single-centre cohorts: the 2021 participants agreed to be screened (self-selected), whereas the 2020 patients were randomly ascertained, and neither should be read as a population-wide risk estimate. The 500 g and 1500 g figures come from studies of PPS users that reported daily doses in mg (the Wang 2021 cohort averaged about 290 to 430 mg per day), i.e. oral use; the Fung paper notes that retinal toxicity had primarily been reported following oral administration, so those figures should not be applied to subcutaneous use. A 2026 case series reported pentosan polysulfate maculopathy in three patients after subcutaneous PPS alone for arthritis, at cumulative doses of 45.5 to 96 g over 7 to 10 years; the authors suggest toxicity can occur with subcutaneous administration alone at much lower doses than with oral use, and advise caution when using subcutaneous PPS (Fung et al., JAMA Ophthalmol 2026, PMID 41379439). The FDA label states that most reported cases occurred after 3 years of use or longer but that cases have been seen with a shorter duration, and that cumulative dose appears to be a risk factor. Course after stopping. The FDA label states that retinal and vision changes may progress even after cessation of treatment. In an 11-patient retrospective case series, no eyes showed a demonstrable improvement after discontinuing PPS, 9 of 11 patients (82%) reported worsening visual symptoms at the final visit, and the authors suggest that the maculopathy continues to evolve after cessation for at least 10 years (Shah et al., JAMA Ophthalmol 2020). Monitoring. The FDA label suggests a baseline retinal examination (including OCT and auto-fluorescence imaging) for all patients within six months of starting treatment and periodically during treatment, and says that if pigmentary changes develop, the risks and benefits of continuing treatment should be re-evaluated because these changes may be irreversible. Symptoms listed in the label are difficulty reading, slow adjustment to low or reduced light environments, and blurred vision.

UK regulatory status

Human use. The MHRA's Drug Safety Update of 19 September 2019 describes pentosan polysulfate as indicated for the treatment of bladder pain syndrome (interstitial cystitis) characterised by either glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency and frequency of micturition, at a recommended 300 mg per day (one 100 mg capsule three times daily), and states that the product information was updated to include the risk of pigmentary maculopathy. The MHRA advised regular ophthalmic examinations for patients taking pentosan polysulfate and asked that suspected adverse reactions be reported to the Yellow Card scheme. The Drug Safety Update's December 2021 note adds that the Summary of Product Characteristics now recommends an ophthalmologic examination after 6 months of use and, if there are no pathologic findings, regularly after 5 years of use. This page does not confirm whether a UK-licensed product is currently on the market: the MHRA product database could not be queried programmatically and the emc search returned no pentosan results on 15 October 2026. Check the MHRA products database before relying on current availability. Knee osteoarthritis. The indication described by the MHRA and by the FDA label is interstitial cystitis bladder pain. The injectable PPS used in the knee osteoarthritis trials discussed on this page was studied as an investigational treatment; we did not find a regulatory approval for it in that indication. Veterinary use. Cartrophen Vet (100 mg sodium pentosan polysulphate per ml) was the subject of adverse-reaction reports to the UK Veterinary Medicines Directorate in dogs between 1991 and 1999 (Hannon et al., 2003). We did not check its current veterinary authorisation, and a veterinary product is not a human medicine. This site does not sell pentosan polysulfate. Nothing here is medical advice; anyone taking it, or considering it, should speak to a prescriber and an eye-care professional.

Medicine status

Unlike most compounds on this site, Pentosan Polysulfate is a prescription medicine for interstitial cystitis (Elmiron). We found no regulatory approval for its use in knee osteoarthritis, where it has been studied in trials. Anyone taking it should follow their prescriber’s advice, including eye examinations as set out in the product information.

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

For full Pentosan Polysulfate research context including mechanism, study citations, and references, see the main Pentosan Polysulfate research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.